Haemonetics Co. (NYSE:HAE) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 11.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 161,452 shares of the medical instruments supplier's stock after selling 19,887 shares during the period. Nuveen Asset Management LLC owned approximately 0.32% of Haemonetics worth $12,606,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. TD Waterhouse Canada Inc. bought a new stake in Haemonetics during the 4th quarter valued at about $25,000. Covestor Ltd boosted its holdings in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after acquiring an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the 4th quarter valued at $62,000. Parkside Financial Bank & Trust boosted its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on HAE shares. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a report on Tuesday, May 20th. Needham & Company LLC lowered their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Barrington Research lowered their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Raymond James reissued a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Price Performance

NYSE:HAE traded down $0.16 during trading hours on Friday, reaching $67.68. 824,062 shares of the company were exchanged, compared to its average volume of 679,583. The stock's 50-day moving average is $63.44 and its 200-day moving average is $70.21. The firm has a market cap of $3.25 billion, a PE ratio of 26.65, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. During the same quarter last year, the firm posted $0.90 earnings per share. Haemonetics's revenue was down 3.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.